Related references
Note: Only part of the references are listed.Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma
Samantha Kendrick et al.
VIRCHOWS ARCHIV (2017)
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma
Sarit E. Assouline et al.
BLOOD (2016)
A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520
Soham D. Puvvada et al.
LEUKEMIA & LYMPHOMA (2016)
CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma
Koichi Takahashi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation
David J. Straus et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433
Jonathan W. Friedberg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma
Jennifer E. Amengual et al.
BLOOD (2013)
Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma
Yasuhiro Oki et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma
Sarah T. Wilkinson et al.
BLOOD (2012)
MHC class II distribution in dendritic cells and B cells is determined by ubiquitin chain length
Jessica K. Ma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Inactivating mutations of acetyltransferase genes in B-cell lymphoma
Laura Pasqualucci et al.
NATURE (2011)
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Ryan D. Morin et al.
NATURE (2011)
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
M. Crump et al.
ANNALS OF ONCOLOGY (2008)
Deacetylase inhibition promotes the generation and function of regulatory T cells
Ran Tao et al.
NATURE MEDICINE (2007)
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
Laurie H. Sehn et al.
BLOOD (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions
LM Rimsza et al.
BLOOD (2006)
Lymphorna incidence patterns by WHO subtype in the United States, 1992-2001
LM Morton et al.
BLOOD (2006)
Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect
P Reddy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project
LM Rimsza et al.
BLOOD (2004)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
CP Hans et al.
BLOOD (2004)
Activation of terminal B cell differentiation by inhibition of histone deacetylation
SC Lee et al.
MOLECULAR IMMUNOLOGY (2003)
Share Paper
